Isis Pharmaceuticals Reports Financial Results and Highlights for ...
PR Newswire (press release) - New York,NY,USA
Inflammatory * Antisense Therapeutics Ltd. advanced ATL1102 targeting VLA-4 into Phase 2 for multiple sclerosis, and added ATL1103, targeting growth hormone ...
See all stories on this topic